公开(公告)号：US11292766B2

公开(公告)日：2022-04-05

申请号：US16713667

申请日：2019-12-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto ,  Norihito Tokunaga ,  Mariko Hirozane

IPC: C07D215/44 ,  C07D211/36 ,  C07D211/24 ,  C07D211/56 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  A61P25/00

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US12077522B2

公开(公告)日：2024-09-03

申请号：US17256330

申请日：2019-06-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Kentaro Rikimaru ,  Yoshihiro Banno ,  Takahiro Matsumoto ,  Norihito Tokunaga ,  Yoshihide Tomata ,  Yuji Ishichi ,  Shogo Marui ,  Tsuneo Oda ,  Tohru Miyazaki ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike

IPC: C07D401/14 ,  C07D211/56 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D211/56 ,  C07D405/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10508083B2

公开(公告)日：2019-12-17

申请号：US16075240

申请日：2017-02-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto

IPC: C07D211/36 ,  A61P25/00

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US11319286B2

公开(公告)日：2022-05-03

申请号：US16635408

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto ,  Yuichi Kajita ,  Satoshi Mikami ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Masaki Daini ,  Masaki Ogino ,  Kohei Takeuchi ,  Tohru Miyazaki ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D207/14 ,  C07D401/14 ,  C07D403/06 ,  A61P25/28

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20170226137A1

公开(公告)日：2017-08-10

申请号：US15421702

申请日：2017-02-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto ,  Norihito Tokunaga ,  Mariko Hirozane

IPC: C07F7/18 ,  C07D211/24 ,  C07D401/14 ,  C07D405/06 ,  C07D413/06 ,  C07D405/14 ,  C07D401/06 ,  C07D409/12 ,  C07D401/12 ,  C07D405/12 ,  C07D417/06 ,  C07D417/14 ,  C07D211/56 ,  C07D409/06

CPC classification number: C07F7/1804 ,  C07D211/24 ,  C07D211/36 ,  C07D211/56 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US10898737B2

公开(公告)日：2021-01-26

申请号：US16410463

申请日：2019-05-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Hiromichi Sugimoto ,  Takahiro Matsumoto

IPC: C07D401/12 ,  A61P25/00 ,  C07D215/44 ,  C07D211/36 ,  C07D211/24 ,  C07D211/56 ,  C07D401/06 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US10287305B2

公开(公告)日：2019-05-14

申请号：US15421702

申请日：2017-02-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Hiromichi Sugimoto ,  Takahiro Matsumoto

IPC: C07D211/56 ,  C07F7/18 ,  C07D211/24 ,  C07D401/14 ,  C07D405/06 ,  C07D413/06 ,  C07D409/06 ,  C07D401/06 ,  C07D409/12 ,  C07D401/12 ,  C07D405/12 ,  C07D417/06 ,  C07D417/14 ,  C07D405/14

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.